Under construction – not a live service
Sign in
Taking peopleNo phase

How eltrombopag is used and how it works in adults with immune thrombocytopenia

Describes eltrombopag use and results in adults with immune thrombocytopenia after steroid treatment.

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Switzerland1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag
Status
Recruiting
People taking part
150 people, planned
Started
25 Jun 2026
Expected to end
29 Sept 2028
Type of study
Observational
Record updated
15 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

This study looks back at medical records of adults with primary immune thrombocytopenia (ITP, low platelets caused by the immune system) treated with eltrombopag after corticosteroids. Doctors in the US, UK and Germany provide the data and fill in a survey.

Age
18 Years to 100 Years; patients aged ≥18 years at the time of diagnosis.
Sex
All sexes.
Disease stage
Confirmed primary ITP.
Earlier treatment
Patients must have had first-line corticosteroid therapy (with or without intravenous immune globulin [IVIg]). They must have started eltrombopag as their first non-steroid ITP treatment between 01 January 2020 and 31 December 2024. At least 6 months of follow-up data must be available after the start, unless the patient died within that time.

Main reasons for not taking part

  • Evans syndrome
  • Secondary ITP (low platelets caused by another disease)
  • Low platelets not caused by the immune system
  • Doctors working for a drug company or regulatory authority involved with ITP treatments

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • HCP inclusion criteria:
  • A licensed HCP (e.g., internal medicine specialist, hematologist, hematologist-oncologist or immunologist etc.) involved in the management of adult patients with primary ITP
  • Actively involved in treatment decision-making for primary ITP patients at the time of the study
  • Have a minimum of 3 years of experience managing patients with primary ITP
  • Currently, managing an average of at least 2 adult primary ITP patients per month, including those treated with eltrombopag
  • Able and willing to complete a web-based survey (approximately 60 to 70 minutes) and abstract data from 2 eligible patient charts
  • Practicing in one of the study countries (US, UK, or Germany)
  • Have access to a computer or mobile device with internet connectivity to complete the survey
  • Not listed as inactive or retired in the panel database; Patient-level inclusion criteria:
  • Confirmed diagnosis of primary ITP
  • Aged ≥18 years at the time of diagnosis
  • Received first-line corticosteroid therapy (with or without intravenous immune globulin [IVIg])
  • Initiated eltrombopag treatment (with or without corticosteroids) as first non-steroidal ITP treatment between 01 January 2020 and 31 December 2024
  • Have at least 6 months of follow-up data available after the index date (unless deceased within that period)

Who cannot take part

  • Diagnosis of Evans syndrome, secondary ITP, or non-immune thrombocytopenia
  • HCP exclusion criteria:
  • Currently employed by a pharmaceutical company or regulatory authority involved in the approval or marketing of treatments for primary ITP
  • Unable to provide data for patients who meet the study's inclusion criteria
  • Not currently managing patients with primary ITP or are not involved in treatment decisions for these patients; Patient-level exclusion criteria:

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to describe the treatment patterns and clinical outcomes of treatment with eltrombopag in primary immune thrombocytopenia (ITP) patients treated with prior corticosteroid therapy.

Read full original descriptionShow less

This study will use secondary data provided by health care professionals (HCPs) for a sample of primary ITP patients, and primary data from a structured HCP survey. Data will be collected from HCPs working in various clinical centers across the United States (US), United Kingdom (UK), and Germany.

The group in the trial

  • Eltrombopag Cohort

    Adult patients diagnosed with primary ITP who initiated eltrombopag treatment between 01 January 2020 and 31 December 2024 following corticosteroid treatment.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Real-world Treatment Patterns and Outcomes of Eltrombopag in Patients With Primary Immune Thrombocytopenia
Plain-language title
How eltrombopag is used and how it works in adults with immune thrombocytopeniaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07587723, who can take part
Record updated
15 October 2026